Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (141-150 of 275) with videos related to

Pageof 28
Sort By:
Oncology and Therapy|November 26, 2025
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung CancerMargarita Majem, Busyamas Chewaskulyong, Zanete Zvirbule, et al.
Frontiers in Oncology|May 21, 2021
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung CancerGiuseppe Bronte, Maurizio Puccetti, Elisabetta Petracci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerRom S Leidner, Pingfu Fu, Bradley Clifford, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Future Oncology (London, England)|May 22, 2020
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of ItalyAlba A Brandes, Andrea Ardizzoni, Fabrizio Artioli, et al.
Oncotarget|May 1, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung CancerBenjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2012
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncologyCesare Gridelli, Filippo de Marinis, Massimo Di Maio, et al.
Future Oncology (London, England)|January 30, 2018
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapiesFederico Cappuzzo, Ross Soo, Maximilian Hochmair, et al.
JAMA Oncology|February 16, 2023
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical TrialsMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Pageof 28

Showing results (141-150 of 275) with videos related to

Sort By:
Pageof 28
Oncology and Therapy|November 26, 2025
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung CancerMargarita Majem, Busyamas Chewaskulyong, Zanete Zvirbule, et al.
Frontiers in Oncology|May 21, 2021
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung CancerGiuseppe Bronte, Maurizio Puccetti, Elisabetta Petracci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerRom S Leidner, Pingfu Fu, Bradley Clifford, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Future Oncology (London, England)|May 22, 2020
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of ItalyAlba A Brandes, Andrea Ardizzoni, Fabrizio Artioli, et al.
Oncotarget|May 1, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung CancerBenjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2012
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncologyCesare Gridelli, Filippo de Marinis, Massimo Di Maio, et al.
Future Oncology (London, England)|January 30, 2018
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapiesFederico Cappuzzo, Ross Soo, Maximilian Hochmair, et al.
JAMA Oncology|February 16, 2023
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical TrialsMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Pageof 28